Table 4 Cox proportional hazard analysis for factors affecting non-completion during LTBI treatment among HCWs.

From: Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital

 

Univariable analysis

Multivariable analysis‡

Hazard ratio (95% CI)

P

Hazard ratio (95% CI)

P

Age group

0.99 (0.96–1.01)

0.314

  

The twenties

Reference

 

Reference

 

Thirties

0.93 (0.35–2.45)

0.890

0.99 (0.32–3.10)

0.983

Forties

0.73 (0.34–1.59)

0.432

0.70 (0.27–1.87)

0.480

Fifties

0.67 (0.26–1.70)

0.401

0.43 (0.16–1.22)

0.113

Sex, male

1.06 (0.55–2.03)

0.863

1.08 (0.48–2.44)

0.856

BMI, kg/m2

0.99 (0.90–1.08)

0.783

1.01 (0.91–1.12)

0.873

Work group

    

Patient-related HCWs

Reference

 

Reference

 

Patient-unrelated HCWs

1.13 (0.54–2.36)

0.742

0.68 (0.28–1.63)

0.384

Comorbidity

    

Hypertension

2.02 (0.49–8.36)

0.331

0.78 (0.17–3.55)

0.746

Chronic liver disease

0.78 (0.19–3.21)

0.726

0.79 (0.13–4.94)

0.803

Adverse reactions

1.11 (0.50–2.49)

0.860

—

 

Hepatotoxicity*

2.89 (1.62–5.46)

<0.001

—

 

No hepatotoxicity

Reference

 

Reference

 

Mild hepatotoxicity

2.26 (1.08–4.74)

0.030

2.34 (1.05–5.21)

0.038

Severe hepatotoxicity

4.71 (2.14–10.34)

<0.001

7.99 (3.05–20.94)

<0.001

Gastrointestinal

0.85 (0.45–1.60)

0.607

0.77 (0.37–1.62)

0.491

Dermatologic

1.52 (0.73–3.16)

0.266

2.25 (0.91–5.55)

0.080

Hematologic

0.64 (0.25–1.62)

0.344

0.69 (0.26–1.85)

0.463

Peripheral neuropathy

2.24 (0.80–6.27)

0.125

3.23 (0.83–12.51)

0.090

Others†

0.90 (0.48–1.67)

0.738

0.98 (0.51–1.88)

0.945

  1. Data are presented as ratios and 95% CIs.
  2. *Mild hepatotoxicity was defined as ALT > UNL, but not meet the definition of severe hepatoxicity. Severe hepatotoxicity was defined as ALT > 3.0 times UNL with symptoms or >5.0 times UNL without symptoms.
  3. †Others include headache, dizziness, general weakness, fatigue, and fever.
  4. ‡Adjusted for age group, sex, BMI, work group, comorbidity (hypertension and chronic liver disease), and each type of adverse events (the severity of hepatotoxicity, gastrointestinal, dermatologic, and hematologic events, peripheral neuropathy, and others).
  5. CI confidence interval, BMI body mass index, HCW healthcare worker, UNL upper normal limit.
Back to article page